Hepatitis D virus and liver transplantation: Indications and outcomes

Muhammad H., Tehreem A., Hammami M. B., Ting P., Idilman R., Gurakar A.

WORLD JOURNAL OF HEPATOLOGY, cilt.13, sa.3, ss.291-299, 2021 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 13 Sayı: 3
  • Basım Tarihi: 2021
  • Doi Numarası: 10.4254/wjh.v13.i3.291
  • Dergi Adı: WORLD JOURNAL OF HEPATOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
  • Sayfa Sayıları: ss.291-299
  • Anahtar Kelimeler: Hepatitis delta virus, Liver transplant, Hepatitis B immunoglobins, Hepatocellular carcinoma, DELTA-VIRUS, HDV INFECTION, B VIRUS, PREVALENCE, DISEASE, ANTIGEN, EPIDEMIOLOGY, PATHOGENESIS, COINFECTION, EXPRESSION
  • Ankara Üniversitesi Adresli: Evet

Özet

Hepatitis D virus (HDV) is a dependent virus that relies on hepatitis B virus for its replication and transmission. Chronic hepatitis D is a severe form of viral hepatitis that can result in end stage liver disease. Currently, pegylated interferon alpha is the only approved therapy for chronic HDV infection and is associated with significant side effects. Liver transplantation (LT) is the only treatment option for patients with end-stage liver disease, hepatocellular carcinoma, or fulminant hepatitis due to coinfection with HDV. As LT for HDV and hepatitis B virus coinfection is uncommon in the United States, most data on the long-term impact of LT on HDV are from international centers. In this review, we discuss the indications and results of LT with treatment options in HDV patients.